Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 127,338

Document Document Title
WO/2018/012582A1
Provided is a blood amino acid level elevation promoter which contains a whey protein hydrolysate as an active ingredient. The elevation of a blood amino acid level in a subject can be promoted by feeding the promoter to the subject.  
WO/2018/012596A1
The purpose of the present invention is to provide a composition for the prevention or treatment of mild cognitive impairment or dementia. The present invention is a composition for the prevention or treatment of mild cognitive impairmen...  
WO/2018/010965A1
Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related m...  
WO/2018/011164A1
The present invention relates to a compound of formula (I) wherein R1 is phenyl, lower alkyl, C3-6-cycloalkyl, -CH2-C3-6-cycloalkyl or bridged C4-6-cycloalkyl, substituted by one, two or three halogen atoms, or by lower alkyl or lower al...  
WO/2018/011181A1
Provided herewith is a pharmaceutical composition comprising, separately or together, a pulsatile release component comprising levodopa and a DOPA decarboxylase inhibitor for the management of OFF-time episodes in patients with Parkinson...  
WO/2018/013420A1
A method of treating an MS patient with homosalate, octyl salicylate, or a combination is disclosed.  
WO/2018/013771A1
Extended release, abuse deterrent dosage forms in which the active ingredient consists essentially of hydrocodone are disclosed, wherein administration of the dosage form to a subject in at least one dose per day over multiple days does ...  
WO/2018/010345A1
The present invention discloses a 5-HT1F receptor agonist, 2,4,6-trifluoro-N-[6-[(1-methyl-piperidin-4-yl)carbonyl]pyri din-2-yl]-benzamide (lasmiditan), and a chloride salt crystalline form thereof. When compared to a solid form of lasm...  
WO/2018/013951A1
Provided herein are compositions and methods for the treatment and of neurodegenerative disorders and levodopa-induced dyskinesias. In particular, A2a receptor antagonists are provided, as well as methods for the use of A2a receptor anta...  
WO/2018/011419A2
The invention relates to a uronic acid monomer for use in the treatment of immune system disturbances, inflammatory diseases, kidney diseases, allergies and neurodegenerative diseases, wherein the uronic acid monomer is α-L-guluronic ac...  
WO/2018/011265A1
The invention relates to compounds of Formula (I), wherein X, R1A, R1B and R2 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of...  
WO/2018/013615A1
Described herein are neuroactive steroids of Formula (I), Formula (V), or Formula (IX) or a pharmaceutically acceptable salt thereof; wherein each instance of R2, R3, R4, R5, R6, R7, R11a, R11b,R12, R16, R17, R19, and ----- are as define...  
WO/2018/011416A1
The invention relates to a uronic acid monomer for use in a method for treating Alzheimer's disease, cancer, disorders caused by oxidative stress, a viral disease, migraine, or diabetes, wherein the uronic acid monomer is β-D-mannuronic...  
WO/2018/013613A1
Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a comp...  
WO/2018/012497A1
The present invention mainly addresses the problem of providing a novel and specific knockout model animal that presents a symptom of a disease accompanied by a synapse abnormality in the brain, a method for producing same, and a therape...  
WO/2018/011073A1
The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using th...  
WO/2018/006750A1
Provided is a secretory protein sDSS1 of a higher primate. The protein can be detected in human blood serum and cerebrospinal fluid. The sDSS1 protein can bind, under non-enzymatic conditions, with an oxidized protein to form a polymer, ...  
WO/2018/007957A1
The present invention refers to novel thiazolo[5,4-d]pyrimidine derivatives that are inverse agonists of the adenosine A2A receptor, to a process for their preparation, to the pharmaceutical compositions containing them and to their use ...  
WO/2018/006646A1
Provided is a decoction for tonifying the kidney, promoting the blood circulation and soothing the liver. The decoction is prepared with Radix bupleuri, white peony root, Cuscuta chinensis, Acorus gramineus, Eucommia ulmoides, Angelica s...  
WO/2018/008733A1
[Problem] To provide a novel pharmaceutical composition which rarely causes adverse side effects, e.g., increase or decrease in body weights, decrease in appetite and decrease in libido, and withdrawal symptoms, and is effective for the ...  
WO/2018/008552A1
[Problem] The purpose of the present invention is to provide: an 11C-labelled catechol derivative exhibiting sufficient radioactivity for obtaining imaging images using a PET device; a PET probe for a phosphorylated tau aggregation inhib...  
WO/2018/006645A1
Provided is a decoction for soothing the liver and tonifying the kidney. The decoction is prepared with 8-12 g of Radix bupleuri, 7-14 g of white peony root, 8-12 g of Cuscuta chinensis, 6-14 g of Acorus gramineus, 4-8 g of Concha Meretr...  
WO/2018/009544A1
The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK...  
WO/2018/009727A1
A method of treating a subject having Alzheimer's disease can include assaying a biological medium obtained from the subject for a biomarker selected from the group consisting of Biomarker 1, Biomarker 2, Biomarker 3, Biomarker 4, Biomar...  
WO/2018/008737A1
The present invention addresses the problem of providing a compound which exerts its effect on the onset mechanism of Parkinson's disease by inhibiting the degeneration and cell death of dopamine-secreting cells, and a therapeutic or pro...  
WO/2018/008770A1
Provided is a method for preventing or treating a disease, said method being characterized in that a viral vector having, integrated thereinto, a gene encoding a protein having a function to kill, stimulate or depress peripheral nerves o...  
WO/2018/009867A1
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, and R6, R11a, and R11b are as defined herein. Compounds of the present invention...  
WO/2018/007842A1
The object of the present invention relates to the formula (1) 1-(4-fluorobenzyl)-1-(1- methylpiperidin-4-yl)-3-[4-(2-methylpropoxy)benzyl]carbamide (pimavanserin) besylate, cyclamate, tosylate, benzoate and mandelate salts, as well as ...  
WO/2018/008749A1
A nucleic acid which can inhibit expression of the MEX3B gene with low cytotoxicity as a side effect, an MEX3B gene expression inhibitor which contains said nucleic acid, a method for inhibiting MEX3B gene expression, and a prophylactic ...  
WO/2018/007331A1
The present invention relates to compounds of formula (I), wherein R1 is phenyl, lower alkyl, C3-6-cycloalkyl, -CH2-C3-6-cycloalkyl, or bridged C3-5-cycloalkyl, optionally substituted by one, two or three substituents, selected from halo...  
WO/2018/004391A1
The invention relates to the chemical-pharmaceutical industry, and specifically to a pharmaceutical composition in tablet form, containing: 2.0-15.0 wt% memantine; 1.5-10.0 wt% melatonin; 65.0-80.0 wt% of a filler, selected from mannitol...  
WO/2018/002760A1
The present invention provides, in part, compounds of Formula (I): or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N- oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the prep...  
WO/2018/001391A1
The present invention discloses an innovate and safe method for effective and safe treatment of peripheral diabetic polyneuritis, tendinopathies, and gingivitis - periodontitis, via the topical administration of the gynura procumbens oil...  
WO/2018/003980A1
The present invention addresses the problem of providing a crystal of a pharmacologically acceptable salt of a bicyclic aminocarboxylic acid derivative. The solution is a crystal of [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3...  
WO/2018/006051A1
Provided herein is a method of detecting or predicting a relapse of multiple sclerosis in an individual afflicted with a form of multiple sclerosis, comprising: (a) providing a blood sample of the individual; (b) testing the blood sample...  
WO/2018/002240A1
The invention concerns a composition comprising probiotic selected from the group consisting of Lactococcus lactis and a combination of Bifidobacterium longum and Lactobacillus rhamnosus, preferably strain Lactococcus lactis or a combina...  
WO/2018/003962A1
2- (Piperidin-1-yl) pyrimidin-4 (3H) -ones characterized by having a 1,8-diazaspiro [4.5] deca-3-ene, 1-oxa-8-azaspiro [4.5] deca-3-ene, 2,8-diazaspiro [4.5] deca-3-ene, 2-oxa-8-azaspiro [4.5] deca-3-ene, 2,9-diazaspiro [5.5] undeca-3-en...  
WO/2018/002938A1
Provided are nucleic acid constructs, Toxoplasma comprising same, pharmaceutical compositions comprising same and methods using same for delivering a protein-of-interest to a tissue-of-interest of a subject, such as the CNS and further t...  
WO/2018/002437A1
Compounds of formula (I): wherein Ra and Rb are as defined in the claims, exhibit alpha2C antagonistic activity and are thus useful as alpha2C antagonists.  
WO/2018/002115A1
A dose regimen comprising the simultaneous administration of two pharmaceutical compositions, wherein the first pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof for once da...  
WO/2018/001335A1
Crystal forms of NBI-98854 (of a structure as represented by formula I), a preparation method therefor and use thereof. The crystal forms of NBI-98854 are named as crystal form CS1 and crystal form CS2 respectively, and can be used in th...  
WO/2018/003857A1
Provided is a curcumine preparation which is highly water soluble, is capable of maintaining a sufficiently high blood concentration of free curcumine and capable of effectively obtaining the pharmacological effect of curcumine by parent...  
WO/2018/005282A1
The invention is directed to a short term induction treatment with anti-N3pGlu Aβ antibodies of a disease characterized by deposition of Aβ in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angi...  
WO/2018/006092A1
The instant disclosure describes compositions comprising mixtures of polypeptides comprising one or more antigenic regions and one or more random copolymer regions. In certain embodiments, the amino acid copolymer compositions of the dis...  
WO/2018/005863A1
This invention is in the area of pyrimidine-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.  
WO/2018/005356A1
Compounds within the scope of the present invention have a Formula 1 or a salt or produg thereof, where ring A is selected from cycloaliphatic; ring B is aryl; R1 is selected from (C1-C10)alkyl, (C3-C10)cycloalkyl, halo, aryl, and hetero...  
WO/2018/002873A1
The present invention relates to the use of 0-(3-piperidino-2-hydroxy-l-propyl)- nicotinic amidoxime (BGP15), its tautomers, enantiomers and pharmaceutically acceptable salts thereof the treatment of diseases characterised at least in pa...  
WO/2018/001918A1
The present invention relates to compounds of formula (I) HetAr is a five or six membered hetaryl group, containing one, two or three heteroatoms, selected from N, O or S; R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, ...  
WO/2018/003583A1
The purpose of the present disclosure is to provide a heat sensitive sheet having an excellent wearing feeling both in an initial state and in use. This heat sensitive sheet has the following configuration. This heat sensitive sheet (1) ...  
WO/2018/002238A1
The invention concerns a composition comprising probiotic selected from the group consisting of Lactococcus lactis and a combination of Bifidobacterium longum and Lactobacillus rhamnosus, preferably strain Lactococcus lactis or a combina...  

Matches 1 - 50 out of 127,338